顺铂联合多西他赛治疗晚期食管癌临床疗效和安全性观察

The clinical efficacy and safety of the advanced esophageal cancer patients by cisplatin and docetaxel

目的探讨顺铂联合多西他赛治疗晚期食管癌临床疗效和安全性观察。方法选取湖南省常德市肿瘤医院2010年8月～2012年12月经诊断明确的晚期食管癌患者50例为研究对象，应用随机数字表法分为两组．对照组采用氟尿嘧啶加顺铂方案，观察组采用顺铂联合多西他赛治疗方案，观察两组患者临床治疗效果及相关毒副反应。结果观察组完全缓解3例（12％），部分缓解12例（48％），总有效率为60％；对照组完全缓解I例（4％），部分缓解8例（32％），总有效率为36％。观察组不良反应包括粒细胞减少5例（20％），血小板减少4例（16％），恶心、呕吐4例（16％），发热2例（8％），化疗相关死亡0例；对照组粒细胞减少8例（32％）；血小板减少6例（24％），呕心、呕吐8例（32％），发热6例（24％），化疗相关死亡2例（8％）。两组患者临床疗效和药物毒副作用相比，差异有统计学意义（X^2=9．441，P〈0．05）。结论顺铂联合多西他赛治疗晚期食管癌疗效较好，安全高效，值得进一步推广应用。

Objective To investigate the clinical efficacy and safety of the advanced esophageal cancer patients by cis- platin and docetaxel. Methods Fifty advanced esophageal cancer patients who were treated in the oncology department of the cancer hospital in changde city of hunan province from August 2010 to December 2012 were chosen as the re- search objects. They were divided into the control group and the observation group by random number table, patients in the control group were given Fluorouracil and Cisplatin,patients in the observation group were given Cisplatin and Do- cetaxel. The clinical treatment effect and the related adverse reaction were evaluated. Results Three patients were complete response （12%） in the observation group, twelve patients were partial response （48%） in the observation group, the total effective rate was 60% in the observation group. One patient were complete response （4%） in the control group, eight patients were partial response （32%） in the control group, the total effective rate was 60% in the control group. The related adverse reaction included granulocytopenia（20%）, thrombocytopenia（16%）, nausea and vomiting （16%）, fever （8%）, and chemotherapy related death （O）.The related adverse reaction included granulocytopenia （32%）, thrombocytopenia （24%）, nausea and vomiting （32% ）, fever （24%）, and chemotherapy related death （8%）, there were significantly difference in the clinical treatment effect and the related adverse reaction （X2=9.441 ,P 〈 0.05 ）. Conclusion The clinical efficacy and safety of the advanced esophageal cancer patients by Cisplatin and Docetaxel is definite, it is safe and effective, worthy of further popularization and application.